Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics Inc (NQ: IOVA )

11.77 +0.45 (+3.93%)
Streaming Delayed Price Updated: 1:04 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Iovance Biotherapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
These Biotech Stocks Could Soar 120% and 295%, According to Wall Street
Catalysts lie ahead for both of these companies. 
Via The Motley Fool
Is Iovance Biotherapeutics Stock a Buy Now?
Let's find out if this biotech can keep up its recent momentum. 
Via The Motley Fool
Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics
These companies are in the early days of their growth stories. 
Via The Motley Fool
2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street
Find out why investment banks up and down Wall Street have big expectations for these stocks. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. 
Via InvestorPlace
Unpacking the Latest Options Trading Trends in Iovance Biotherapeutics
Via Benzinga
(IOVA) - Analyzing Iovance Biotherapeutics's Short Interest
Via Benzinga
Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead
This company's growth story is about to get moving with gusto. 
Via The Motley Fool
Piper Sandler Maintains Overweight Rating for Iovance Biotherapeutics: Here's What You Need To Know
Via Benzinga
Truist Securities Maintains Buy Rating for Iovance Biotherapeutics: Here's What You Need To Know
Via Benzinga
1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17?
Its revenue is set to grow, and one of its trials is no longer paused. 
Via The Motley Fool
Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analyst
With its first approval in hand, attention is now on the top line. 
Via The Motley Fool
Could Iovance Biotherapeutics Stock Help You Become a Millionaire?
Does Iovance Biotherapeutics stock possess enough upside to generate life-changing returns for your portfolio? 
Via The Motley Fool
Spotlight on Iovance Biotherapeutics: Analyzing the Surge in Options Activity
Via Benzinga
Iovance Biotherapeutics: Q4 Earnings Insights
Via Benzinga
Iovance Biotherapeutics's Earnings: A Preview
Via Benzinga
Is Iovance a Buy After Its First Regulatory Win?
Iovance Biotherapeutics has found a new way to treat cancer. 
Via The Motley Fool
Why Iovance Biotherapeutics Stock Got Trounced on Thursday
A robust rally ended abruptly with the publication of the company's latest fundamentals. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Iovance Therapeutics Stock Has Skyrocketed Over 100% so Far This Year. Is It Still a Buy?
More gains might be on the way for this high-flying biotech stock. 
Via The Motley Fool
3 Stocks Flashing Recent Insider Buying Signals
One way to spot an opportunity is by paying attention to insider buying stocks. After all, it’s the insiders that know their company. 
Via InvestorPlace
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential. 
Via InvestorPlace
Unpacking the Latest Options Trading Trends in Iovance Biotherapeutics
Via Benzinga
Iovance Biotherapeutics Unusual Options Activity For February 22
Via Benzinga
1 Soaring Growth Stock That Could Rise Another 53%, According to Wall Street
A successful launch of its first approved therapy could push shares of this innovative new cancer drug developer through the roof. 
Via The Motley Fool
This Biotech Stock Has 47% Upside, According to 1 Wall Street Analyst
It has good news in hand and plenty of room to grow. 
Via The Motley Fool
2 Top Biotech Stocks That Wall Street Thinks Could Soon Double in Value
These two businesses have viable paths to making investors richer -- possibly soon. 
Via The Motley Fool
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of International Flavors & Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.